The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A community hospital cancer services approach to the reduction of OP-35 rule hospitalizations.
 
John F. Deeken
Research Funding - BeiGene; Merck
 
Erik Dvergsten
No Relationships to Disclose
 
Chiara Pierattini
No Relationships to Disclose
 
Mouneer Odeh
No Relationships to Disclose
 
Timothy Lewis Cannon
Honoraria - AstraZeneca; Bayer; Sirflex; Sirflex
Consulting or Advisory Role - Intermountain Healthcare
Other Relationship - Navican/ Intermountain Healthcare
 
Kathleen Kiernan Harnden
Honoraria - Clinical Care Options; E-Health Now
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Merck; Seagen
 
Jeanny B. Aragon-Ching
Honoraria - Astellas Scientific and Medical Affairs Inc; Bristol-Myers Squibb; EMD Serono; Merck KGaA; Merck/Pfizer; Pfizer/EMD Serono
Consulting or Advisory Role - Algeta/Bayer; Amgen; AstraZeneca; AstraZeneca/MedImmune; AVEO; Bayer; Dendreon; EMD Serono; Exelixis; Immunomedics; Janssen Biotech; Merck; Pfizer; Pfizer/Myovant; Sanofi; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen-Ortho; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Algeta/Bayer; Astellas Pharma; Bristol Myers Squibb; Dendreon; EMD Serono
 
Raymund Cuevo
No Relationships to Disclose
 
Michael L. Maitland
Employment - Intellia Therapeutics
Leadership - United Therapeutics (I)
Stock and Other Ownership Interests - Intellia Therapeutics
Consulting or Advisory Role - Actelion/Janssen (I); Aerami (I); Aerovate (I); Altavant (I); Bayer (I); Keros Therapeutics (I); Medtronic (I); Merck (I); Reata Pharmaceuticals (I); United Therapeutics (I)
Research Funding - AstraZeneca (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Methods of gene editing, unrestrictively licensed to Intellia Therapeutics, Inc.
 
Sanja Karovic
No Relationships to Disclose